prescribe Dexcom G7: the most accurate CGM system1 for confident diabetes management
From the #1 recommended continuous glucose monitoring brand2,3
the most accurate CGM system1
For reliable treatment decisions that lead to proven results4-8
Industry-leading MARD (in adults):
8.2% for Dexcom G79 vs. 8.9% for Freestyle Libre 310
MARD (mean absolute relative difference) is a statistical measure of CGM accuracy; the lower the number the better.
Clinically proven to4-8:
Clinically proven to4-8:
-
Lower A1C
-
Increase time in range
-
Reduce hyper- and hypoglycemia
-
Improve quality of life
Smart device sold separately.*
the simple CGM system
For effortless diabetes management that leads to better adherence†,1
2x faster warmup than FreeStyle Libre10,12 for easy setup and a quick start for you and your patients
Simple all-in-one wearable for easy application9
60% smaller‡ for comfortable, discreet wear
the most covered CGM brand13
For affordable care without compromising quality for the broadest audience of people with diabetes
One-third of patients with commercial insurance have a $0 copay§,14
Dexcom has 3x more patients paying $0 compared to FreeStyle Libre.||,15
our CGM portfolio can help patients with all types of diabetes gain greater glucose control4-8
The Dexcom CGM Portfolio is an expanding line of CGM systems that support a broad range of people with diabetes. Now you can simply prescribe the powerful CGM system that works best for your patients’ individual needs.
Dexcom G7
the most accurate CGM system1
An intuitive user experience with the advanced accuracy that only Dexcom offers
Dexcom G6
the most connected CGM system1
Industry-leading connectivity with pumps and pens for powerful integrated diabetes control
Dexcom G6 integrates with 60+ connected partners for seamless diabetes management
As the first Class II integrated CGM (iCGM) system authorized by the FDA, Dexcom works with a range of connected insulin pens and automated insulin delivery (AID) system partners. We continue to pursue collaboration opportunities with product and digital health brands, offering a multifaceted approach to effective diabetes management for patients, caregivers, and healthcare providers.
clinical resources to support you
DIaMonD Study1 shows that Dexcom CGM use improves glucose control in adults with type 1 diabetes using insulin injections.
*Smart devices sold separately. To view a list of compatible devices, visit dexcom.com/compatibility.
†Based on use out of 30 days.
‡Compared to a prior generation Dexcom CGM System.
§Refers to estimated out-of-pocket cost for eligible commercially insured patients from the Dexcom CGM System sensor when claims are adjudicated as a pharmacy benefit, and includes benefits and offerings through available Dexcom programs, such as the voucher program. Actual cost may vary and is subject to individual insurance coverage.
||For those with commercial pharmacy coverage.
1 Dexcom, data on file, 2022.
2 dQ&A US Q1 2021 Diabetes Connections Patient Panel Report. 2021;69-72.
3 Seagrove HCP Survey Q1 2021.
4 Welsh JB, et al. J Diabetes Sci Technol. 2022:19322968221099879.
5 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39.
6 Beck RW, et al. JAMA. 2017;317(4):371-378.
7 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
8 Martens T, et al. JAMA. 2021;325(22):2262-227.
9 Dexcom G7 CGM System User Guide.
10 FreeStyle Libre 3 User Guide.
11 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39.
12 FreeStyle Libre 2 User Guide.
13 Managed Markets Insights & Technology, LLC. MMIT Analytics, June 2022.
14 IQVIA February 2022.
15 Data on file, IQVIA 8/21-8/22.